( OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, ...

President and Chief Executive Officer — Shawn K. Singh Chief Operating Officer — Joshua S. Prince Vice President, Corporate ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

RWD and RWE are reshaping the design of clinical trials, making them smarter, faster, and more efficient. Read more here: ...

Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial ...

In this live interview on Bloomberg World, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, discusses the ...

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses ...

Most return-to-office mandates aren’t solving a collaboration problem. They’re solving an assessment problem that physical ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

Over time, places like Monte Carlo and Las Vegas turned gambling into a global industry, packed with bright lights, high stakes, and non-stop traffic. Casinos like the Bellagio, MGM Grand, and Marina ...